PDCD1 and neoplasm: Strong anti–PD-1 combination benefit was observed in four additional settings: B16F10, 1956 sarcoma, MCA205, and KP.mLama4 (38) tumor models (Supplementary Fig. S5A–S5I), all of which showed limited activity with anti–PD-1 monotherapy in the treatment settings used.